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Introduction
Signaling by the multifunctional cytokine TGFβ1 is regulated 
by other secreted proteins that infl  uence TGFβ1’s biological 
  activity and localization (Annes et al., 2003). Central to these 
interactions is the fact that TGFβ1 is secreted in a latent form. 
TGFβ1 latency arises from a noncovalent interaction between 
TGFβ1 and its propeptide, latency-associated peptide (LAP). In 
addition to blocking access of TGFβ1 to TGFβ receptors, LAP 
interacts via disulfi  de bonds with proteins of the latent TGFβ-
binding protein (LTBP) family (Fig. 1). The trimolecular com-
plex of TGFβ1, LAP, and LTBP is referred to as the large latent 
complex and is thought to be the major secreted form of latent 
TGFβ1. LTBPs bind to matrix molecules, thereby anchoring 
 latent TGFβ1 in the extracellular space, and infl  uence the release 
of TGFβ1 from LAP, a process called latent TGFβ1 activation 
(Annes et al., 2004). Two other isoforms of TGFβ (TGFβ2 
and -3) are secreted in similar latent forms.
Proposed TGFβ1 activators include thrombospondin-1 
(TSP1), proteases such as plasmin and matrix metalloproteinases 
(MMPs), the integrins αvβ6 and αvβ8 (which recognize an 
RGD sequence in LAP), and reactive oxygen species (Sato et al., 
1990; Barcellos-Hoff and Dix, 1996; Crawford et al., 1998; 
Munger et al., 1999; Ribeiro et al., 1999; Yu and Stamenkovic, 
2000; Mu et al., 2002). By degrading LAP or changing its 
  conformation, these activators permit TGFβ1 to engage TGFβ 
receptors. Because TGFβ1 regulates numerous processes (immune 
function, cell proliferation, apoptosis, extracellular matrix for-
mation, and vascular development, among others), one can 
speculate that multiple TGFβ1 activation mechanisms are used 
to activate TGFβ1 in diverse contexts. However, we lack a com-
prehensive picture that connects specifi  c biological effects of 
TGFβ1 with specifi  c TGFβ1 activators.
In some cases, deletion of the gene encoding a puta-
tive TGFβ1 activator results in a phenotype consistent with a 
TGFβ1 defi  cit. For example, mice lacking TSP1 or the integrin 
β6 subunit (Tsp1
−/− and Itgb6
−/− mice) develop infl  ammation, 
although it is not as severe as that in Tgfb1
−/− mice, which 
develop marked infi  ltrates of activated T cells in multiple or-
gans and die soon after weaning (Shull et al., 1992; Huang 
et al., 1996; Crawford et al., 1998). In addition, Itgb6
−/− mice 
are protected from TGFβ-dependent fi  brotic tissue reactions 
(Munger et al., 1999). Some embryos lacking αvβ8 (Itgb8
−/−) 
have defective vasculogenesis that appears identical to defects 
observed in a subset of Tgfb1
−/− embryos (Dickson et al., 
1995; Zhu et al., 2002). However, knockouts of genes encod-
ing other putative TGFβ1 activators, such as plasminogen and 
various MMPs, do not result in phenotypes clearly related to 
TGFβ1 defi  cits.   Although Itgb6
−/−;Tsp1
−/− mice have a more 
severe infl  ammatory phenotype than either single-null animal 
(Ludlow et al., 2005), these mice do not fully phenocopy 
Tgfb1
−/− mice.
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plex before it can engage TGFβ receptors. One mechan-
ism of latent TGFβ1 activation involves interaction of the 
integrins αvβ6 and αvβ8 with an RGD sequence in LAP; 
other putative latent TGFβ1 activators include thrombo-
spondin-1, oxidants, and various proteases. To assess the 
contribution of RGD-binding integrins to TGFβ1 activation 
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functional variant of the RGD sequence (RGE). Mice with 
this mutation (Tgfb1
RGE/RGE) display the major features of 
Tgfb1
−/− mice (vasculogenesis defects, multiorgan inﬂ  am-
mation, and lack of Langerhans cells) despite production 
of normal levels of latent TGFβ1. These ﬁ  ndings indicate 
that RGD-binding integrins are requisite latent TGFβ1 
  activators during development and in the immune system.
Correspondence to John S. Munger: john.munger@med.nyu.edu
Abbreviations used in this paper: E, embryonic day; ES, embryonic stem; LAP, 
latency-associated peptide; LC, Langerhans cell; LTBP, latent TGFβ-binding 
  protein; MMP, matrix metalloproteinase; TSP1, thrombospondin-1.
The online version of this article contains supplemental material.JCB • VOLUME 176 • NUMBER 6 • 2007  788
To delineate the role of RGD-binding integrins in genera-
tion of TGFβ1 activity, we created mice with a selective loss 
of integrin-mediated TGFβ1 activation. To do this, we made a 
TGFβ1 gene mutation that encodes an inactive version of LAP’s 
integrin-binding site (RGE instead of RGD) and used embry-
onic stem (ES) cells containing the mutant gene to generate 
mice. These mice produce latent TGFβ1 that cannot interact 
with RGD-binding integrins.
Results and discussion
A targeting vector was made by inserting two contiguous frag-
ments of Tgfb1 DNA, with appropriate mutations in the frag-
ment containing exon 5, into the cloning sites of the pKSloxPNT 
vector (Fig. 1 A). One mutation creates a conservative single 
amino acid change (D246E) within the RGD motif located near 
the C terminus of LAP (Fig. 1 B), and the other creates a new 
restriction site that can be used for identifi  cation of the mutant 
allele. The vector was used to transfect ES cells, and cells with 
correct targeting of Tgfb1 were injected into blastocysts to gen-
erate mice carrying the Tgfb1 mutation (Fig. 1 C). These mice 
were crossed with Cre-deleter mice to remove the loxP-fl  anked 
Neo cassette from the targeted gene.
Tgfb1
−/− mice display several abnormalities (Shull et al., 
1992), the most prominent of which is T cell–mediated multi-
organ infl  ammation that leads to death soon after weaning. In 
  addition, a strain-dependent fraction of Tgfb1
−/− embryos dies 
around embryonic day (E) 10 because of failure of yolk sac vas-
culogenesis and/or hematopoiesis (Dickson et al., 1995). Also, 
Tgfb1
−/− mice lack Langerhans cells (LCs), which are dendritic 
cells residing in the epidermis (Borkowski et al., 1997). We pre-
dicted that Tgfb1
RGE/RGE mice would have an incomplete version 
of the Tgfb1
−/− phenotype, as occurs in Tsp1
−/−, Itgb6
−/−, and 
Itgb8
−/− mice (see Table I for a comparison of knockout 
phenotypes). However, Tgfb1
RGE/RGE mice display the cardinal 
features of Tgfb1
−/− mice.
Tgfb1
RGE/RGE mice appear normal at birth but are smaller 
than littermates by 14 d and have markedly reduced survival 
(Fig. 2 B). Histologic examination of Tgfb1
RGE/RGE mice be-
tween the ages of 18 and 28 d revealed marked mononuclear 
cell infi  ltration of multiple tissues, in particular, the heart, lung, 
liver, stomach, and pancreas (which were abnormal in >85% of 
mice examined), and occasionally in the CNS (Fig. 2 A and not 
depicted). In the lung, infl  ammatory lesions are usually local-
ized around bronchi and larger vessels and sometimes diffusely 
within alveolar walls; in the liver, lesions are localized within 
portal canals. We did not note infl  ammation in the skin or 
 kidney. These  fi  ndings are similar to those reported for Tgfb1
−/− 
mice. A side-by-side comparison of the infl  ammatory lesions in 
Tgfb1
RGE/RGE and Tgfb1
−/− mice reveals them to be indistin-
guishable (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200611044/DC1). Because the β6-integrin subunit, 
which is expressed predominantly in epithelial cells, is up-
  regulated by injury and infl  ammation, we assessed β6 expression 
in 3-wk-old Tgfb1
RGE/RGE mice. β6 protein is markedly increased 
in lung and gastric epithelium (Fig. 2 C) and is occasionally 
  increased in biliary epithelium (not depicted). We did not detect 
β6 protein expression in the heart.
Figure 1.  Generation of mice with a targeted mutation of Tgfb1. (A) Sche-
matic of Tgfb1 (top) and fragments thereof used for insertion in targeting 
vector (bottom). Box shows mutations (solid underlines) introduced in exon 5 
to encode a BstUI restriction site (dashed underline) and the D-to-E muta-
tion. Restriction sites: A, ApaI; B, BamHI; H, HindIII; S, SalI. Neo, neomycin 
resistance cassette; TK, thymidine kinase cassette. (B) The TGFβ1 mRNA 
encodes a protein sequence consisting of a signal peptide (SP), propeptide 
(LAP), and the TGFβ1 cytokine (top). The integrin-binding motif RGD 
is near the C terminus of LAP. The processed latent factor consists of non-
covalently associated disulﬁ  de-linked homodimers of the LAP and TGFβ1 
monomers (bottom). LAP can be disulﬁ  de linked via cys-33 to one of the 
cysteine-repeat domains (ovals) of LTBP-1, -3, or -4. (C) PCR genotyping 
  results from Tgfb1
+/+, Tgfb1
+/RGE, and Tgfb1
RGE/RGE mice.
Table I. Phenotypes of mice with mutations in genes encoding integrin subunits, TSP1, TGF𝗃1, or TGF𝗃3
Phenotype Gene
Itgav
−/− Itgb6
−/− Itgb8
−/− Tsp1
−/− Tgfb1
−/−, Tgfb1
RGE/RGE Tgfb3
−/−
Autoimmune syndrome NT Mild inﬂ  ammation 
(lung and skin)
NT Inﬂ  ammation 
(lung and pancreas)
Lethal autoimmune 
syndrome
NT
Abnormal vasculogenesis 
 ( E10)
80% of embryos 0% 60% of embryos 0%  50% of embryos 0%
LC deﬁ  cit NT Reduced numbers NT NA Absent NT
Abnormal central nervous 
 system vascular development
100% at birth 0% 100% at birth 0% 0% 0%
Cleft palate 100% 0% 10% at birth 0% 0% 100%
NT, not tested because of early lethality; NA, data not available.INTEGRIN-MEDIATED TGF𝗃1 ACTIVATION IN VIVO • YANG ET AL.  789
We also compared the developmental consequences of the 
RGE mutation with the developmental abnormalities observed 
in Tgfb1
−/− mice. We determined the genotype of mice born to 
parents heterozygous for the mutant Tgfb1 allele. Of 378 births, 
36.4% were Tgfb1
+/+, 50.2% were Tgfb1
+/RGE, and 13.4% were 
Tgfb1
RGE/RGE. Thus, there is a substantial difference between the 
Mendelian ratios 1:2:1 (+/+:+/RGE:RGE/RGE) and the ob-
served ratios of  1:1.4:0.4, indicating an embryonic lethality 
of  50% associated with the Tgfb1
RGE/RGE genotype and  25% 
for the Tgfb1
+/RGE genotype. To determine when lethality oc-
curs, we collected embryos for genotyping and histologic anal-
ysis. Of 146 E10.5 embryos, 24.3% were Tgfb1
+/+, 50% were 
Tgfb1
+/RGE, and 25.7% were Tgfb1
RGE/RGE. Therefore, embry-
onic death occurs at or after E10.5. Approximately half of the 
E10.5 Tgfb1
RGE/RGE yolk sacs had grossly evident anemia and/or 
absence of normal vasculature (Fig. 3, A and B). Histological 
abnormalities consisted variably of a paucity of vessels, absence 
of hematopoietic cells, and extensive buckling between the 
  mesodermal and endodermal layers (Fig. 3, C–E). Similar fi  ndings 
have been reported for Tgfb1
−/− mice and mice expressing 
dominant-negative TGFβ receptors (Dickson et al., 1995; 
  Oshima et al., 1996).
We also compared the LC status of Tgfb1
RGE/RGE mice with 
that of Tgfb1
−/− mice. Normally, peripheral blood monocytes 
enter the epidermis and differentiate into LCs, but Tgfb1
−/− 
mice completely lack LCs (Borkowski et al., 1997). The target 
cell for TGFβ signaling appears to be the LC or a precursor, not 
epithelial cells, and TGFβ1 production by nonmarrow-derived 
cells is suffi  cient for LC production. We compared the presence 
of LCs in Tgfb1
RGE/RGE mice and littermate normal controls by 
staining for LCs in epidermal sheets obtained from the back or 
ear. LCs are absent from both sites (Fig. 3 F), aside from very 
rare small clusters of LCs in skin from ears, typically near the 
ear edge (not depicted).
Because  αvβ6 is functional in the epidermis, in that 
Itgb6
−/− mice develop skin infl  ammation (Huang et al., 1996), 
we suspected that this integrin might be the major or sole activa-
tor of TGFβ1 involved in LC generation. Therefore, we exam-
ined epidermal sheets from Itgb6
−/− and Itgb6
+/+ mice 
(C57BL/6 strain) for the presence of LCs (Fig. 3 G). LCs are 
  almost completely absent from Itgb6
−/− ear epidermis. In con-
trast, epidermal sheets from the backs of Itgb6
−/− mice have 
about half as many LCs as equivalent samples from Itgb6
+/+ 
mice (Fig. 3, G and H). Although some Itgb6
−/− mice develop 
infl  ammatory skin lesions at sites of tissue trauma, character-
ized by hair loss and macrophage infi  ltration, these changes 
were not present in skin of our Itgb6
−/− mice, and the lack of 
LCs in Tgfb1
−/− mice is independent of the infl  ammatory pheno-
type (Borkowski et al., 1997). We conclude that the TGFβ1 
  required for LC generation is activated by RGD-binding 
  integrins, but the integrins involved vary by region. In ear 
 epidermis,  the  αvβ6 integrin is required for LC generation, 
whereas in back epidermis, αvβ6 appears to contribute but is 
not absolutely necessary.
The phenotypes of Tgfb1
−/− and Tgfb1
RGE/RGE mice are 
similar to that of Foxp3
−/− mice, which lack CD4+CD25+ 
regulatory T cells (Tregs). However, we detected no difference 
in the abundance of Tregs among CD4+ cells isolated from 
spleens of 8–10-d-old Tgfb1
+/+ and Tgfb1
RGE/RGE mice, assessed 
as the percentage of either CD25+ or Foxp3+ cells (unpub-
lished data). Because the phenotype of Tgfb1
RGE/RGE mice is 
highly similar to that of Tgfb1
−/− mice in the processes we 
examined, we assessed in vivo transcription and translation of 
the mutated Tgfb1 gene to confi  rm that the observed phenotype 
is not due to impaired gene function. The targeting vector intro-
duced a Neo expression sequence into the intron between exons 
5 and 6 of Tgfb1, and such sequences often interfere with 
  expression of the targeted gene. Serum levels of TGFβ1 refl  ect 
Figure 2.  Tgfb1
RGE/RGE mice develop fatal multiorgan inﬂ  ammation. (A) Histology of inﬂ  ammatory lesions in lung, heart, liver, and stomach of Tgfb1
RGE/RGE 
mice (hematoxylin and eosin staining). (B) Kaplan-Meier survival curve for Tgfb1
RGE/RGE mice (n = 54). (C) Increased expression of β6 protein in stomach 
and lung epithelium of Tgfb1
RGE/RGE mice.JCB • VOLUME 176 • NUMBER 6 • 2007  790
both tissue production of TGFβ1 and release of TGFβ1 by 
platelets during clotting and can be measured with a luciferase-
based bioassay after heating the serum to activate latent TGFβ1 
(see Materials and methods). The assay is performed with and 
without anti-TGFβ antibody to confi  rm specifi  city. Serum lev-
els of TGFβ1 were reduced in Tgfb1
+/RGE mice and undetect-
able in Tgfb1
RGE/RGE mice when the Neo sequence was present 
(Fig. 4 A). However, after removal of the Neo sequence, serum 
levels of latent TGFβ1 in mice heterozygous or homozygous 
for the RGE mutation were equivalent to those in Tgfb1
+/+ mice 
(Fig. 4 B). Levels of latent TGFβ1 in serum-free medium con-
ditioned by lung fi  broblasts derived from Tgfb1
+/+, Tgfb1
+/RGE, 
or Tgfb1
RGE/RGE mice were also equivalent (Fig. 4 C). To confi  rm 
that the genetic manipulations had not altered mRNA sequence, 
we used RNA from Tgfb1
RGE/RGE lung fi  broblasts to amplify the 
coding sequence by RT-PCR and found no changes other than 
the expected mutations introduced in exon 5. Tgfb1 gene 
  expression, measured by semiquantitative RT-PCR using RNA 
isolated from lung, liver, and heart, was not measurably affected 
by the Tgfb1 RGE mutation (Fig. 4 D and not depicted).
The RGD-to-RGE mutation eliminates integrin-mediated 
TGFβ1 activation in cell culture experiments but does not ap-
pear to affect other LAP functions, such as TGFβ inhibition or 
interaction with LTBP. The D-to-E mutation is conservative, 
and the location of the RGD sequence is remote from the TSP1-
binding site and an MT1-MMP cleavage site (Ribeiro et al., 
1999; Mu et al., 2002). Purifi  ed recombinant LAP with the 
RGD-to-RGE mutation does not support adhesion by cells ex-
pressing αvβ6 or αvβ8 (Munger et al., 1999; Mu et al., 2002), 
indicating that these integrins cannot effectively engage the 
  mutated binding site. In contrast, LAP’s interaction with TGFβ1 
appears unaffected by the RGE mutation. Recombinant LAP 
binds and inhibits the bioactivity of recombinant TGFβ1, and 
the dose–response curve for this inhibition is not affected by the 
RGE mutation (Fig. 4 E); also, cells transfected with TGFβ1-
RGE cDNA secrete normal amounts of latent TGFβ1 that is 
bioactive after activation by heating (not depicted).
We also tested the ability of the RGE mutant form of LAP 
to form disulfi  de linkages with LTBP1 and to be incorporated 
into ECM, because these functions are critical for activation. 
CHO cells expressing LTBP1 (Annes et al., 2004) were trans-
fected with cDNAs encoding wild-type or RGE TGFβ1, and 
conditioned media were immunoblotted with anti-LAP anti-
body. Equal amounts of high molecular weight bands consistent 
with LTBP1–LAP complexes (Annes et al., 2004) are seen, 
along with small amounts of monomeric LAP ( 37 kD). We 
previously showed that cells expressing αvβ6 do not activate 
soluble latent TGFβ1-RGE (Annes et al., 2002). In cell culture 
conditions similar to those in previous reports (Annes et al., 
2002, 2004), the RGD and RGE forms of latent TGFβ1 are 
equivalently incorporated into cell-derived matrix, but only the 
RGD form of matrix-bound latent TGFβ1 is activated by αvβ6- 
or αvβ8-expressing cells (Fig. S2, available at http://www.jcb
.org/cgi/content/full/jcb.200611044/DC1).
In summary, loss of latent TGFβ1 activation by RGD-
binding integrins in vivo recapitulates the major features of 
Tgfb1
−/− mice. We conclude that in these biological contexts, 
essentially all active TGFβ1 is generated in conjunction with 
integrin–LAP interactions. Issues requiring clarifi  cation include 
the identity of the RGD-binding integrins involved, the role of 
RGD-binding integrins in activation of TGFβ3, and the role of 
nonintegrin mechanisms of TGFβ1 activation.
Figure 3.  Defects in vascular development and LCs in 
Tgfb1
RGE/RGE mice. (A and B) Vasculature is present in wild-type 
yolk sac (arrows) but is not identiﬁ  able in an E12.5 Tgfb1
RGE/RGE 
embryo. (C–E) Histologic appearance of control and 
Tgfb1
RGE/RGE E12.5 yolk sacs. In the mutant yolk sacs, there is 
poor contact between endothelial and mesothelial layers and, 
in E, absence of blood cells. (F) LCs are absent in epidermis 
from back and ear of Tgfb1
RGE/RGE mice. (G) LCs are less 
abundant in back epidermis (arrows) and absent in ear epi-
dermis of Itgb6
−/− mice. (H) Compared with control mice, 
Itgb6
−/− mice have fewer LCs in back epidermis. P = 0.001. 
Error bars indicate means ± SEM.INTEGRIN-MEDIATED TGF𝗃1 ACTIVATION IN VIVO • YANG ET AL.  791
Integrins are heterodimers of α and β subunits. Of 24 
mammalian integrins, 8 (αvβ1,  αvβ3,  αvβ5,  αvβ6,  αvβ8, 
αIIbβ3, α5β1, and α8β1) bind RGD sequences in their respec-
tive ligands. Of these, 2 (αvβ6 and αvβ8) clearly activate 
TGFβ1 in vitro and in vivo (Munger et al., 1999; Mu et al., 
2002). αvβ5 binds LAP and, when expressed by scleroderma 
fi  broblasts, activates latent TGFβ; however, activation has not 
been noted in other αvβ5-expressing cells (Asano et al., 2005; 
Araya et al., 2006). Three other RGD-binding integrins (αvβ1, 
αvβ3, and α8β1) bind LAP but have not been shown to activate 
latent TGFβ1 when expressed in cultured mammalian cells 
(Munger et al., 1998; Lu et al., 2002; Ludbrook et al., 2003). 
The phenotypes of αv-, β6-, and β8-null mice (Huang et al., 
1996; Bader et al., 1998; Zhu et al., 2002) are somewhat similar 
to those of Tgfb1
−/− mice (Table I), but the phenotypes of 
other integrin-null mice are not (α5- and β1-null mice die early 
in embryogenesis, precluding comparison). Nevertheless, it is 
plausible that these LAP-binding but non–TGFβ-activating 
 integrins  promote  TGFβ1 activation in vivo, perhaps by con-
centrating latent TGFβ1 at cell surfaces where it might be acti-
vated by another process.
TGFβ3-LAP contains an RGD sequence, and latent 
TGFβ3 is activated by αvβ6 and αvβ8 expressed in cultured 
cells (Annes et al., 2002; Araya et al., 2006). The phenotypes of 
Itgb6
−/− and Tgfb3
−/− mice do not overlap, but 10% of Itgb8
−/− 
mice have cleft palate (Zhu et al., 2002), which occurs in all 
Tgfb3
−/− mice (Kaartinen et al., 1995; Proetzel et al., 1995; 
 Table  I).  Therefore,  αvβ8 may be partially responsible for 
TGFβ3 activation during palate formation.
There are numerous reports of physiologic TGFβ1 activa-
tion by nonintegrin mechanisms, such as TSP1, proteases, and 
oxidants. Although our results suggest that RGD-binding integ-
rins play a dominant role in TGFβ1 activation, several caveats 
exist. First, our results are limited to three phenotypes that are 
evident within the fi  rst few weeks of life, and it is possible that 
other TGFβ1-mediated processes occur independently of integrin-
mediated activation. Second, integrins likely act in parallel or 
in series with nonintegrin mechanisms to generate TGFβ1 
  signaling in vivo. For example, αvβ8 and MT1-MMP coopera-
tively activate TGFβ1 at cell surfaces (Mu et al., 2002), and 
proteolytic activity releases latent TGFβ1 from the ECM (Annes 
et al., 2003), thereby potentially enhancing access of latent 
TGFβ1 to integrins for activation under some circumstances. 
The phenotype of TSP1-null mice partially overlaps that of 
Tgfb1
−/− mice (Table I), suggesting that TSP1 may cooperate 
with RGD-binding integrins in TGFβ1 activation.
Our fi  ndings reveal a critical role for RGD-binding integ-
rins in the generation of TGFβ1 signaling activity in three dis-
parate processes (control of infl  ammation, vasculogenesis, and 
LC genesis) and illustrate the utility of a subtle genetic mutation 
approach to complement gene knockout studies. Further work 
is needed to establish which RGD-binding integrins are  involved 
in specifi  c TGFβ1 effects and how integrins interact with other 
molecules involved in TGFβ1 activation.
Materials and methods
Creation of targeting vector containing a Tgfb1 exon 5 mutation
A 1.4-kb mouse TGFb1 cDNA was used to screen a 129/SvEv mouse 
Lambda FIX II Library. A 13-kb clone containing Tgfb1 exons 1–6 was re-
striction mapped. HindIII digestion generated a 6-kb fragment containing 
exons 2–5 and a contiguous 5-kb fragment containing most of the intron 
between exons 5 and 6. These were subcloned into pBluescriptSK. Exon 5 
encodes the RGD
246 in TGFβ1-LAP. We used the QuikChange site-directed 
mutagenesis kit (Stratagene) to mutate the codon encoding D
246 to a codon 
encoding E and to create an adjacent silent mutation creating a BstUI site 
(cg/cg). The mutagenesis primers were ggatcagccccaaacgtcgcggcgagct-
gggcaccatccatgac and gtcatggatggtgcccagctcgccgcgacgtttggggctgatcc.
A targeting vector was made using the pKSloxPNT plasmid (a gift 
from A. Joyner, New York University School of Medicine, New York, NY). 
The plasmid containing the 5-kb HindIII fragment was digested with BamHI 
to generate a 3.3-kb BamHI fragment (one BamHI site is derived from the 
pBluescript cloning site), which was inserted at the BamHI cloning site. The 
6-kb HindIII fragment containing the RGD-to-RGE mutation was excised 
with SalI and XhoI and ligated into the targeting vector at the SalI site. A 
clone with correct insert orientation (SalI site closest to the Neo cassette 
  destroyed) was identiﬁ  ed. The vector was extensively sequenced to conﬁ  rm 
that genomic sequences and loxP sites were intact and correctly oriented.
Transfection of ES cells and identiﬁ  cation of targeted clones
The targeting vector was linearized by SalI digestion. 50 μg of DNA was 
used to transfect 5 × 10
6 W4 ES cells by electroporation. ES cells were 
Figure 4.  The RGE mutation does not affect Tgfb1 gene 
  expression, LAP inhibitory function, or latent TGF𝗃1 processing 
and secretion. Serum TGFβ1 levels in Tgfb1
+/+, Tgfb1
+/RGE, 
and Tgfb1
RGE/RGE mice before (A) and after (B) removal of a 
Neo sequence within the mutated Tgfb1 allele. (C) TGFβ lev-
els in medium conditioned by lung ﬁ  broblasts derived from 
Tgfb1
+/+, Tgfb1
+/RGE, and Tgfb1
RGE/RGE mice. Effects of an 
anti-TGFβ antibody active against all three TGFβ isoforms 
(α-TGFβ) and of an antibody that inhibits only TGFβ1 (α-TGFβ1) 
are shown. Error bars indicate means ± SEM. (D) Tgfb1 gene 
expression was assessed by semiquantitative RT-PCR using 
RNA isolated from Tgfb1
+/+, Tgfb1
+/RGE, and Tgfb1
RGE/RGE 
lung ﬁ   broblasts. Reverse-transcribed β-actin mRNA was 
  ampliﬁ  ed as a control. (E) Recombinant wild-type and RGE 
mutant LAP inhibit equally the activity of recombinant TGFβ1, 
measured with a cell-based luciferase assay. Luciferase activ-
ity, expressed as relative light units (RLU), is proportional to 
TGFβ activity. (F) Wild-type and RGE mutant TGFβ1 cDNAs 
were expressed in LTBP1S-expressing CHO cells. Secreted 
proteins were separated by SDS-PAGE in nonreducing condi-
tions and probed with an anti-LAP antibody. Large latent com-
plex (LLC) indicates migration of the LAP–LTBP1 complex.JCB • VOLUME 176 • NUMBER 6 • 2007  792
  selected with 200 μg/ml G418 and 2 μM gancyclovir. Correctly targeted 
clones were identiﬁ  ed by Southern blot using external probes (exons 1 and 6). 
With ApaI-digested genomic DNA, an exon 6 probe revealed an 8-kb 
fragment of the wild-type Tgfb1 gene and a 7.4-kb band in the targeted lo-
cus (RGE). With EagI-digested genomic DNA, an exon 1 probe revealed a 
20-kb fragment of the wild-type Tgfb1 gene and an 11-kb band in the tar-
geted locus. Three ES clones with a homologous recombination event were 
identiﬁ  ed, two of which included the RGE mutation.
Generation of homozygous mutant mice
An ES clone was used for injecting blastocysts of C57BL/6J mice. The chi-
meric mice were bred with C57BL/6J mice to achieve germline trans-
mission. Tgfb1
+/RGE mice were bred to generate homozygous mice. TGFβ1 
protein levels were undetectable in these mice because of the presence of 
Neo. Cre-deleter mice (a gift of A. Joyner) were crossed with Tgfb1
+/RGE 
mice. Two Cre lines were used, one of Swiss-Webster background and 
the other C57BL/6J. Removal of Neo was conﬁ   rmed by PCR showing 
  un  detectable product using primers for Neo (gaacaagatggattgcacgc 
and gaagaactcgtcaagaagggc) and an appropriate-sized fragment using 
primers ﬂ   anking the Neo insertion site (gaggagacaagatctctcaga and 
caatggccctacacacacacagag).
Mice were bred on the two mixed backgrounds determined by the 
background of the Cre mouse: C57BL/6 + 129SvEvTac and C57BL/6 + 
129SvEvTac + Swiss-Webster. Phenotypes on the two backgrounds were 
indistinguishable. Results reported here are from the C57BL/6 + 
129SvEvTac background.
Primary ﬁ  broblasts
Lungs from newborn mice were minced and placed in tissue culture dishes 
with high-glucose DME containing 10% FCS, glutamine, penicillin, and 
streptomycin to allow lung ﬁ  broblasts to proliferate. Within the ﬁ  rst three 
passages, cells were transfected with an expression plasmid containing 
cDNA for the SV40 large T antigen.
TGF𝗃 bioassay
Sera from wild-type and mutant mice were heated to 80°C for 10 min to 
activate latent TGFβ and then diluted 1:4 in DME. Bioactive TGFβ was 
measured by adding samples to mink lung epithelial cells stably transfected 
with a TGFβ-responsive luciferase reporter construct and then assaying cell 
lysates for luciferase activity (Abe et al., 1994). Conditioned media were 
obtained by incubating equal numbers of cells in DME containing 0.1% 
BSA overnight, heat activated as described, diluted with an equal volume 
of DME, and assayed as described. Samples were tested in the presence 
and absence of a TGFβ1-speciﬁ  c inhibitory antibody (R&D Systems) or an 
inhibitory antibody against all three TGFβ isoforms (1D11; R&D Systems). 
Results are the means of triplicates ± SEM.
TGF𝗃 inhibitory activity of LAP
Recombinant simian wild-type and RGE LAP were produced as described 
previously (Munger et al., 1999). Active recombinant TGFβ1 was added 
to DME supplemented with 0.1% BSA. Aliquots of this stock were com-
bined with varying concentrations of recombinant LAP and then added to 
mink lung epithelial reporter cells and assayed as described.
TGF𝗃1 transfections and LAP immunoblotting
CHO-K7 cells stably expressing LTBP1 (a gift from J. Annes and D. Rifkin, 
New York University) were transfected with expression vectors contain-
ing cDNA encoding different forms of TGFβ using Lipofectamine Plus 
(Invitrogen) or with empty plasmid as described previously (Annes et al., 
2002, 2004). The next day, cells were used to condition serum-free 
  medium (DME supplemented with 0.1% BSA and glutamine) for 24 h. 
  Immunoblotting with anti-LAP mAb VB3A9 was done as described pre-
viously (Annes et al., 2004).
TSP1 activation of TGF𝗃1
The three types of serum-free conditioned media obtained as described 
above were incubated with 11 nM of puriﬁ  ed, stripped TSP1 (a gift 
from J. Murphy-Ullrich, University of Alabama, Birmingham, AL; Ribeiro 
et al., 1999) for 1 h at 37°C and then assayed with mink lung epithelial 
reporter cells as described, with or without addition of a TGFβ-inhibitory 
antibody (1D11).
RT-PCR
Primary cultures of lung ﬁ  broblasts (see Primary ﬁ  broblasts) were used as 
the source of RNA. RNA was extracted and reverse transcribed by stan-
dard techniques. PCR was performed using primers based on the 5′ and 
3′ ends of the TGFβ1 coding sequence (5′ primer, tactgccgcttctgctcccac; 
and 3′ primer, caggagcgcacaatcatgttg). The resulting PCR product was the 
expected size and was completely sequenced. Semiquantitative RT-PCR 
was done with RNA isolated from lungs, liver, and heart of Tgfb1
+/+ and 
Tgfb1
RGE/RGE mice (forward primer, exon 4: cggaatacagggctttcgatt; and 
  reverse primer, exon 6: cttgctgtactgtgtgtccaggc). The PCR program was 
94°C for 4 min; 94°C for 45 s, 60°C for 45 s, and 72°C for 90 s for 20, 
25, or 29 cycles; and 72°C for 10 min. Ampliﬁ  cation of β-actin cDNA 
(primers used: atctggcaccacaccttctacaatgagctgcg and cgtcatactcctgcttgct-
gatccacatctgc) was done as a control.
Immunohistochemistry
5-μm sections of formalin-ﬁ  xed tissue were used for detection of the β6-
  integrin subunit. Endogenous peroxidase activity was quenched with 3% 
hydrogen peroxide in methanol for 15 min. Antigen retrieval was with 
  Digest-All 3 Pepsin (Zymed Laboratories) for 5–7 min. Blocking was with 
avidin/biotin block solution (Vector Laboratories) followed by 0.5% casein 
solution for 15 min. Anti-β6 monoclonal antibody ch2A1 (a gift from 
S.   Violette, Biogen Idec, Cambridge, MA), a humanized version of a mouse 
anti-β6 IgG mAb, was used at 0.5 μg/ml in 0.1% BSA for 1 h at room 
temperature. A Vectastain ABC kit (Vector Laboratories) with anti-human 
secondary antibody was used according to directions, with 3,3-diamino-
benzidine/hydrogen peroxide as chromogen (Sigma Fast tablets; Sigma-
Aldrich) and hematoxylin counterstaining. Speciﬁ   city was conﬁ  rmed  by 
absent staining on lung sections from Itgb6
−/− mice.
LC immunostaining
Ia+ LCs in epidermal sheets were detected as described previously (Thomas 
et al., 2001). For counts, epidermal sheets from four Itgb6
−/− and three 
wild-type mice were stained (6–12 sheets per mouse; mean 8.6). A digital 
image (400×) of each stained sheet was captured, and all LCs were 
counted. The mean cell count for each mouse was the average count of all 
sheets for that mouse. Statistical signiﬁ   cance of the difference between 
means for wild-type and Itgb6
−/− mice was assessed by two-tailed t-test.
Flow cytometry analysis of CD4+CD25+ and Foxp3+ splenocytes
CD4+ splenocytes were isolated from total splenocytes stained by negative 
selection with immunomagnetic beads (CD4+ T Cell isolation kit; Miltenyi 
Biotec). Flow cytometry was performed after labeling with phycoerythrin-
conjugated anti-CD4 and FITC-conjugated anti-CD25 mAbs (BD Bio-
sciences) or isotype controls to determine the fraction of CD4+ cells that were 
CD25+. To determine the fraction of CD4+ cells that were Foxp3+, cells 
were labeled with FITC-conjugated anti-CD4 antibody, and intracellular 
staining with a phycoerythrin-conjugated anti-Foxp3 antibody was per-
formed (eBioscience).
Protocol for genotyping RGE mice
Primers are C  G  G  A  A  T  A  C  A  G  G  G  C  T  T  T  C  G  A  T  T   and G  G  T  A  C  G  G  G  C  A  T  T  C  T  G-
G  A  T  A  C  . PCR program is 94°C for 4 h and then 30 cycles of 94°C for 
30 min, 60°C for 30 min, and 72°C for 50 min, followed by 72°C for 
10 h. PCR products are digested with BstUI and electrophoresed on 
  agarose gels.
Image acquisition and manipulation
A light microscope (DM LB; Leica) captured images with a 10, 20, or 
40× objective lens at room temperature. Permount imaging medium was 
used. The camera used was a Spot Insight Color (model 3.2.0), and 
the acquisition software was the Spot program version 4.0.9, both by 
  Diagnostic Instruments.
Online supplemental material
Fig. S1 shows the similarity of inﬂ   ammatory lesions in Tgfb1
RGE/RGE 
and  Tgfb1
−/− mice. Fig. S2 shows data from transfection experiments 
demonstrating that the normal and RGE forms of latent TGFβ1 can be 
incorporated into ECM and that cells expressing αvβ6 or αvβ8 can 
activate the normal form but not the RGE form of ECM-bound latent 
TGFβ1. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200611044/DC1.
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